Atli Thorarensen , Martin E Dowty 1 , Mary Ellen Banker , Brian Juba , Jason Jussif , Tsung Lin , Fabien Vincent , Robert M Czerwinski , Agustin Casimiro-Garcia , Ray Unwalla , John I Trujillo , Sidney Liang , Paul Balbo , Ye Che , Adam M Gilbert , Matthew F Brown , Matthew Hayward , Justin Montgomery , Louis Leung 1 , Xin Yang 1 , Sarah Soucy , Martin Hegen , Jotham Coe , Jonathan Langille , Felix Vajdos , Jill Chrencik , Jean-Baptiste Telliez
Mar 09 2017
Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of highly selective JAK3 inhibitors has eluded the scientific community. A significant effort within our research organization has resulted in the identification of the first orally active JAK3 specific inhibitor, which achieves JAK isoform specificity through covalent interaction with a unique JAK3 residue Cys-909. The relatively rapid resynthesis rate of the JAK3 enzyme presented a unique challenge in the design of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwanted off-target reactivity. This effort resulted in the identification of 11 (PF-06651600), a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor 11 led to its evaluation in several human clinical studies.